The Latest Cardiac and Vascular News
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to…
THOUSAND OAKS, Calif., Aug. 26, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran […]
THOUSAND OAKS, Calif., April 27, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023. “We delivered 14% volume growth driven by the breadth of our portfolio and strong demand for our products globally,” said Robert A. Bradway, chairman and chief executive officer. “We look forward to closing […]
Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events Analysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a) Concentration Irrespective of Baseline Level Amgen Convenes First LDL-C Action Summit to Help Improve State of Cardiovascular Disease Care in the U.S. […]
Unique Community-Based Partnership With the Association of Black Cardiologists and Morehouse School of Medicine to Identify Study Sites and Participants Observational Study to Better Understand Associations Between Lp(a) Levels and Atherosclerotic Cardiovascular Disease (ASCVD) in an Underrepresented Patient Population THOUSAND OAKS, Calif., Feb. 22, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the African American […]
AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS THOUSAND OAKS, Calif., Jan. 31, 2023 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021. “We executed effectively in 2022, delivering strong volume growth, advancing numerous […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of olpasiran. Arrowhead is further eligible to receive up to an additional $535 million in aggregate development, regulatory, and […]
Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented a new analysis […]
Olpasiran Reduced Lipoprotein(a) Levels by More Than 95% in Patients With Established ASCVD Amgen is Initiating a Phase 3 Cardiovascular Outcomes Trial Based on These Results Data Simultaneously Published in the New England Journal of Medicine THOUSAND OAKS, Calif. , Nov. 6, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its […]
THOUSAND OAKS, Calif., Nov. 3, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2022. Key results include: Total revenues decreased 1% to $6.7 billion in comparison to the third quarter of 2021, resulting from a 1% decline in global product sales, which reflected 8% volume growth offset primarily […]
